An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-α2b in patients with multiple myeloma maintained on a steady dose of interferon-α2b

Annals of Oncology

Volumn 18, Issue 8, 2007, Pages 1388-1394

  Sirohi, B ^a,b   Powles, R ^a,b,c   Lawrence, D ^a,b   Treleaven, J ^a,b   Kulkarni, S ^a,b   Leary, A ^a,b   Rudin, C ^a,b   Horton, C ^a,b   Morgan, G ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c Parkside Cancer Centre   (United Kingdom)

Author keywords

Maintenance therapy; Myeloma; Pegylated interferon; Quality of life

Indexed keywords

ALPHA2B INTERFERON; IMMUNOGLOBULIN; PEGINTERFERON ALPHA2B; STEROID;

ADULT; AGED; ANOREXIA; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; BACKACHE; CANCER FATIGUE; CANCER PAIN; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COMMON COLD SYMPTOM; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIARRHEA; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DRY SKIN; EMOTIONALITY; FEMALE; FLU LIKE SYNDROME; FUNCTIONAL ASSESSMENT; HERPES SIMPLEX; HUMAN; INFECTION; KIDNEY DYSFUNCTION; LETHARGY; LIVER DYSFUNCTION; LIVER FUNCTION TEST; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE MYELOMA; NEUTROPHIL COUNT; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOCIAL INTERACTION; THROMBOCYTE COUNT; TREATMENT DURATION;

EID: 34548150428     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm180     Document Type: Article

References (37)

1. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
2. Rajkumar SV, Hayman S, Gertz M et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 21: 4319-4323.
3. Richardson PG, Schlossman RL, Weller E et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063-3067.
4. Rajkumar SV, Hayman SR, Lacy MQ et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106: 4050-4053.
5. Richardson PG, Sonneveld P, Schuster MW. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
6. Oakervee HE, Popat R, Curry N et al. PAD combination therapy PS-341/ bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129: 755-762.
7. Yang HH, Vescio R, Schenkein D et al. A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341, velcade and melphalan in patients with relapsed or refractory multiple myeloma. Clin Lymphoma 2003; 4: 119-122.
8. Badros A, Barlogie B, Morris C et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001; 97: 2574-2579.
9. Sirohi B, Powles R, Mehta J et al. An elective single autograft with high-dose melphalan: Single-center study of 451 patients. Bone Marrow Transplant 2005; 36: 19-24.
10. Child JA, Morgan W, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
11. Porcher R, Levy V, Fermand JP et al. Evaluating high dose therapy in multiple myeloma: Use of quality-adjusted survival analysis. Qual Life Res 2002; 11: 91-99.
12. Ludwig H, Drach J, Tóthová E et al. Thalidomide-dexamethasone versus melphalan-prednisolone as first line treatment in elderly patients with multiple myeloma: An Interim analysis. Blood 2005; 106: 231a.
13. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-965.
14. Shire NJ, Sherman KE. Clinical trials of treatment for hepatitis C virus infection in HIV-infected patients: Past, present, and future. Clin Infect Dis 2005; 41: S63-68.
15. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
16. Shepherd J, Brodin H, Cave C et al. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: A systematic review and economic evaluation. Health Technol Assess 2004; 8: 1-125.
17. Ludwig FE. Interferon-alpha treatment in multiple myeloma: Meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol 2000; 11: 1427-1436.
18. The Myeloma Trialists' Collaborative Group. Interferon as therapy for multiple myeloma: An individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001; 113: 1020-1034.
19. Bukowski RM, Tendier C, Cutler D et al. Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon alpha-2b formulation. Cancer 2002; 95: 389-396.
20. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
21. Stead ML, Brown JM, Velikova G et al. Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. Br J Haematol 1999; 104: 605-611.
22. Hjermstad MJ, Fossa SD, Bjordal K et al. Test/retest study of the European Organisation for Research and Treatment of Cancer core quality-of-life questionnaire. J Clin Oncol 1995; 13: 1249-1254.
23. Trotti A, Byhardt R, Stetz J et al. Common toxicity criteria: Version 2.0: An improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000; 47: 13-47.
24. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer 1975, 36: 842-854.
25. Bladé J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123.
26. Mellstedt H, Bjorkholm M, Johannson B et al. Interferon therapy in myelomatosis. Lancet 1979; 1: 245-248.
27. Mandelli F, Awisati G, Amadori S et al. Maintenance treatment with recombinant interferon alpha 2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990; 322: 1430-1434.
28. Cunningham D, Powles R, Malpas J et al. A randomized trial of maintenance Interferon following high-dose chemotherapy in multiple myeloma: Long-term follow-up results. Br J Hematol 1998; 102: 495-502.
29. Pulsoni A, Awisati G, Petrucci MT et al. The italian experience on interferon as maintenance treatment in multiple myeloma: Ten years after. Blood 1998; 92: 2184-2185.
30. Drayson MT, Chapman CE, Dunn JA et al. MRC trial of a2b-interferon maintenance therapy in first plateau phase of multiple myeloma. Br J Haematol 1998; 101: 195-202.
31. Browman GP, Bergsagel D, Sicheri D et al. Randomized trial of interferon maintenance in multiple myeloma: A study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1995; 13: 2354-2360.
32. Blade J, San Miguel JF, Escudero ML et al. Maintenance treatment with interferon alpha-2b in multiple myeloma: A prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology). Leukemia 1998; 12: 1144-1148.
33. Salmon SE, Crowley JJ, Grogan TM et al. Combination chemotherapy, glucocorticoids and interferon alfa in the treatment of multiple myeloma: A Southwest Oncology Group Study. J Clin Oncol 1994; 12: 2405-2414.
34. Schaar CG, Kluin-Nelemans HC, te Marvelde C. Interferon-α as maintenance therapy in patients with multiple myeloma. Ann Oncol 2005; 16: 634-639.
35. Ludwig H, Fritz E, Neuda J et al. Patient preferences for interferon alfa in multiple myeloma. J Clin Oncol 1997; 15: 1672-1679.
36. Powles R, Raje N, Horton C et al. Comparison of interferon tolerance after autologous bone marrow or peripheral blood stem cell transplants for myeloma patients who have responded to induction therapy. Leuk Lymphoma 1995; 18: 179-184.
37. Fairclough DL. Patient reported outcomes as endpoints in medical research. Stat Methods Med Res 2004; 13: 115-138.